- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | |
|---|---|---|
| Mi | 53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report | |
| Mi | Biotech VC raises $200M to focus on Japan's 'untapped source' of innovation | |
| Mi | Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor | |
| Mi | Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC | |
| Mi | Why 'emboldened' activist investors are taking the fight to biotechs | |
| Mi | Organon axes 'biggest potential opportunity' after flunking phase 2 trial | |
| Di | Catalio's $400M fund takes advantage of 'historic buyer's market in biotech' | |
| Di | Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach | |
| Di | Concentra acquires IGM Biosciences, continuing M&A streak with struggling biotechs | |
| Di | ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations | |
| Di | Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering atai merger | |
| Di | Sanofi takes up option on Adagene biospecific and invests $25M, shielding partner from runway risk | |
| Di | BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent | |
| Di | Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker | |
| Mo | 'Emergency' at Apple Tree: VC sues key investor, warns portfolio biotechs are on brink of collapse | |
| Mo | Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 | |
| Mo | Pfizer expands AI-powered small-molecule discovery collab with XtalPi | |
| Mo | AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market | |
| Mo | INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering plans | |
| Mo | Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA | |
| Mo | Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trial | |
| Fr | CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle | |
| Fr | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | |
| Fr | Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials | |
| 26.06. | Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .